3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Delirium
2
Thrombocytopenia
1
Stomatitis
1
Pleural Effusion
1
Pelvic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Ovarian Neoplasms
1
Otolaryngeal Cancer
1
Metabolic Diseases
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hemostatic Disorders
1
Head and Neck Neoplasms
1
Emergence Delirium
1
Chemotherapy-Related Cognitive Impairment
1
Anemia, Aplastic
1
Interventions
Cytarabine
85
Cyclophosphamide
58
Azacitidine
57
fludarabine
52
venetoclax
41
fludarabine phosphate
41
Busulfan
30
Filgrastim
23
Whole-Body Irradiation
22
Decitabine
21
Mycophenolic Acid
20
Methotrexate
19
Mitoxantrone
18
Etoposide
18
Antilymphocyte Serum
18
Cyclosporine
17
Clofarabine
17
Tacrolimus
16
Granulocyte Colony-Stimulating Factor
16
Peripheral Blood Stem Cell Transplantation
15
Daunorubicin
15
Melphalan
13
thymoglobulin
11
Thiotepa
11
Stem Cell Transplantation
11
Interleukin-2
11
Idarubicin
10
Gemtuzumab
9
Cord Blood Stem Cell Transplantation
9
aldesleukin
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Leukemia, Myeloid, Acute
×
Saline Solution
×
Clear all
NCT04571645
2024-04-15
AML
Jazz Pharmaceuticals
Phase 3
Terminated
9 enrolled
9 charts